NO20033343L - Farmasöytiske doseringsformer av epothiloner for oral administrasjon - Google Patents
Farmasöytiske doseringsformer av epothiloner for oral administrasjonInfo
- Publication number
- NO20033343L NO20033343L NO20033343A NO20033343A NO20033343L NO 20033343 L NO20033343 L NO 20033343L NO 20033343 A NO20033343 A NO 20033343A NO 20033343 A NO20033343 A NO 20033343A NO 20033343 L NO20033343 L NO 20033343L
- Authority
- NO
- Norway
- Prior art keywords
- epothilones
- dosage forms
- oral administration
- pharmaceutical dosage
- pharmaceutical
- Prior art date
Links
- 239000002552 dosage form Substances 0.000 title 1
- 229930013356 epothilone Natural products 0.000 title 1
- HESCAJZNRMSMJG-KKQRBIROSA-N epothilone A Chemical class C/C([C@@H]1C[C@@H]2O[C@@H]2CCC[C@@H]([C@@H]([C@@H](C)C(=O)C(C)(C)[C@@H](O)CC(=O)O1)O)C)=C\C1=CSC(C)=N1 HESCAJZNRMSMJG-KKQRBIROSA-N 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US26422801P | 2001-01-25 | 2001-01-25 | |
| US29001901P | 2001-05-11 | 2001-05-11 | |
| PCT/US2002/002518 WO2002058701A1 (en) | 2001-01-25 | 2002-01-25 | Pharmaceutical dosage forms of epothilones for oral administration |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| NO20033343D0 NO20033343D0 (no) | 2003-07-24 |
| NO20033343L true NO20033343L (no) | 2003-09-24 |
Family
ID=26950349
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20033343A NO20033343L (no) | 2001-01-25 | 2003-07-24 | Farmasöytiske doseringsformer av epothiloner for oral administrasjon |
Country Status (26)
| Country | Link |
|---|---|
| US (2) | US6576651B2 (is) |
| EP (1) | EP1361877A1 (is) |
| JP (1) | JP2004528287A (is) |
| KR (1) | KR20040025888A (is) |
| CN (1) | CN1268336C (is) |
| AR (1) | AR035078A1 (is) |
| BG (1) | BG108027A (is) |
| BR (1) | BR0206695A (is) |
| CA (1) | CA2434584A1 (is) |
| CZ (1) | CZ20032023A3 (is) |
| EE (1) | EE200300329A (is) |
| HR (1) | HRP20030674A2 (is) |
| HU (1) | HUP0303800A3 (is) |
| IL (1) | IL156759A0 (is) |
| IS (1) | IS6892A (is) |
| MX (1) | MXPA03006476A (is) |
| NO (1) | NO20033343L (is) |
| NZ (1) | NZ526871A (is) |
| PE (1) | PE20020853A1 (is) |
| PL (1) | PL368636A1 (is) |
| RU (1) | RU2291695C2 (is) |
| SK (1) | SK9212003A3 (is) |
| TW (1) | TWI250017B (is) |
| UY (1) | UY27138A1 (is) |
| WO (2) | WO2002058699A1 (is) |
| YU (1) | YU58103A (is) |
Families Citing this family (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6204388B1 (en) * | 1996-12-03 | 2001-03-20 | Sloan-Kettering Institute For Cancer Research | Synthesis of epothilones, intermediates thereto and analogues thereof |
| WO1999001124A1 (en) | 1996-12-03 | 1999-01-14 | Sloan-Kettering Institute For Cancer Research | Synthesis of epothilones, intermediates thereto, analogues and uses thereof |
| US20050043376A1 (en) * | 1996-12-03 | 2005-02-24 | Danishefsky Samuel J. | Synthesis of epothilones, intermediates thereto, analogues and uses thereof |
| US6867305B2 (en) | 1996-12-03 | 2005-03-15 | Sloan-Kettering Institute For Cancer Research | Synthesis of epothilones, intermediates thereto and analogues thereof |
| US6605599B1 (en) | 1997-07-08 | 2003-08-12 | Bristol-Myers Squibb Company | Epothilone derivatives |
| US6780620B1 (en) * | 1998-12-23 | 2004-08-24 | Bristol-Myers Squibb Company | Microbial transformation method for the preparation of an epothilone |
| JP2003502449A (ja) | 1999-06-10 | 2003-01-21 | ハネウエル・インターナシヨナル・インコーポレーテツド | フォトリソグラフィ用スピンオンガラス反射防止コーティング |
| US6824879B2 (en) | 1999-06-10 | 2004-11-30 | Honeywell International Inc. | Spin-on-glass anti-reflective coatings for photolithography |
| US8618085B2 (en) * | 2000-04-28 | 2013-12-31 | Koasn Biosciences Incorporated | Therapeutic formulations of desoxyepothilones |
| NZ526871A (en) | 2001-01-25 | 2006-01-27 | Bristol Myers Squibb Co | Pharmaceutical dosage forms of epothilones for oral administration |
| IL156580A0 (en) * | 2001-01-25 | 2004-01-04 | Bristol Myers Squibb Co | A method for formulating an epothilone analog for parenteral use and pharmaceutical preparations including an epothilone analog |
| BR0207487A (pt) | 2001-02-20 | 2004-08-10 | Brystol Myers Squibb Company | Método de tratamento de tumores em mamìferos e uso de compostos de epotilona |
| WO2002072085A1 (en) * | 2001-03-14 | 2002-09-19 | Bristol-Myers Squibb Company | Combination of epothilone analogs and chemotherapeutic agents for the treatment of proliferative diseases |
| WO2003044600A1 (en) | 2001-11-15 | 2003-05-30 | Honeywell International Inc. | Spin-on anti-reflective coatings for photolithography |
| AU2003218107A1 (en) * | 2002-03-12 | 2003-09-29 | Bristol-Myers Squibb Company | C12-cyano epothilone derivatives |
| TW200403994A (en) * | 2002-04-04 | 2004-03-16 | Bristol Myers Squibb Co | Oral administration of EPOTHILONES |
| TW200400191A (en) * | 2002-05-15 | 2004-01-01 | Bristol Myers Squibb Co | Pharmaceutical compositions and methods of using C-21 modified epothilone derivatives |
| US6921769B2 (en) | 2002-08-23 | 2005-07-26 | Sloan-Kettering Institute For Cancer Research | Synthesis of epothilones, intermediates thereto and analogues thereof |
| DE60330407D1 (de) | 2002-08-23 | 2010-01-14 | Sloan Kettering Inst Cancer | Synthese von Epothilonen, Zwischenprodukte davon, Analoga und ihre Verwendung |
| US7649006B2 (en) | 2002-08-23 | 2010-01-19 | Sloan-Kettering Institute For Cancer Research | Synthesis of epothilones, intermediates thereto and analogues thereof |
| AU2003279911A1 (en) * | 2002-10-09 | 2004-05-04 | Kosan Biosciences, Inc. | Therapeutic formulations |
| US7390503B1 (en) | 2003-08-22 | 2008-06-24 | Barr Laboratories, Inc. | Ondansetron orally disintegrating tablets |
| MXPA06002257A (es) * | 2003-08-26 | 2006-05-17 | Shire Holdings Ag | Farmaceutica que comprende compuestos de lantano. |
| US20050171167A1 (en) * | 2003-11-04 | 2005-08-04 | Haby Thomas A. | Process and formulation containing epothilones and analogs thereof |
| DK1687066T3 (da) * | 2003-11-14 | 2012-11-26 | Brigham & Womens Hospital | Fremgangsmåder til immunmodulering |
| US8053159B2 (en) | 2003-11-18 | 2011-11-08 | Honeywell International Inc. | Antireflective coatings for via fill and photolithography applications and methods of preparation thereof |
| US20090004277A1 (en) * | 2004-05-18 | 2009-01-01 | Franchini Miriam K | Nanoparticle dispersion containing lactam compound |
| US7244765B2 (en) * | 2004-06-25 | 2007-07-17 | Cytokine Pharmasciences, Inc | Guanylhydrazone salts, compositions, processes of making and methods of using |
| US20060069136A1 (en) * | 2004-09-24 | 2006-03-30 | Ulrich Klar | Use of Epothilones in the treatment of bone metastasis |
| EP1824458A1 (en) * | 2004-11-18 | 2007-08-29 | Bristol-Myers Squibb Company | Enteric coated bead comprising epothilone or an epothilone analog, and preparation and administration thereof |
| AR052142A1 (es) * | 2004-11-18 | 2007-03-07 | Bristol Myers Squibb Co | Perla recubierta enterica que comprende ixabepilona, y preparacion y administracion de la misma |
| AR057325A1 (es) * | 2005-05-25 | 2007-11-28 | Progenics Pharm Inc | Sintesis de (s)-n-metilnaltrexona, composiciones farmaceuticas y usos |
| US8158152B2 (en) * | 2005-11-18 | 2012-04-17 | Scidose Llc | Lyophilization process and products obtained thereby |
| US8642246B2 (en) | 2007-02-26 | 2014-02-04 | Honeywell International Inc. | Compositions, coatings and films for tri-layer patterning applications and methods of preparation thereof |
| CA2722371C (en) | 2008-04-24 | 2016-06-21 | Bristol-Myers Squibb Company | Use of epothelone d in treating tau-associated diseases including alzheimer's disease |
| US8557877B2 (en) | 2009-06-10 | 2013-10-15 | Honeywell International Inc. | Anti-reflective coatings for optically transparent substrates |
| DE102010021637A1 (de) | 2010-05-26 | 2011-12-01 | Bayer Schering Pharma Aktiengesellschaft | Substituierte 5-Fluor-1H-Pyrazolopyridine und ihre Verwendung |
| US8864898B2 (en) | 2011-05-31 | 2014-10-21 | Honeywell International Inc. | Coating formulations for optical elements |
| CN102276433B (zh) * | 2011-06-30 | 2016-04-20 | 南昌大学 | 木豆素c及其衍生物及其在制备抗癌药物中的应用 |
| JP6803842B2 (ja) | 2015-04-13 | 2020-12-23 | ハネウェル・インターナショナル・インコーポレーテッドＨｏｎｅｙｗｅｌｌ Ｉｎｔｅｒｎａｔｉｏｎａｌ Ｉｎｃ． | オプトエレクトロニクス用途のためのポリシロキサン製剤及びコーティング |
Family Cites Families (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE4138042C2 (de) | 1991-11-19 | 1993-10-14 | Biotechnolog Forschung Gmbh | Epothilone, deren Herstellungsverfahren sowie diese Verbindungen enthaltende Mittel |
| DK1186606T4 (da) | 1995-11-17 | 2011-12-05 | Biotechnolog Forschung Gmbh | Epothilonderivater, deres fremstilling og anvendelse |
| DE19542986A1 (de) | 1995-11-17 | 1997-05-22 | Biotechnolog Forschung Gmbh | Epothilon-Derivate und deren Verwendung |
| DE19639456A1 (de) | 1996-09-25 | 1998-03-26 | Biotechnolog Forschung Gmbh | Epothilon-Derivate, Herstellung und Mittel |
| US6441025B2 (en) * | 1996-03-12 | 2002-08-27 | Pg-Txl Company, L.P. | Water soluble paclitaxel derivatives |
| DE69735057T2 (de) * | 1996-03-12 | 2006-08-31 | PG-TXL Co., L.P., Houston | Wasserlösliche paclitaxel-prodrogen |
| EP0923583A1 (de) | 1996-08-30 | 1999-06-23 | Novartis AG | Verfahren zur herstellung von epothilonen und zwischenprodukte innerhalb des verfahrens |
| DE19645362A1 (de) | 1996-10-28 | 1998-04-30 | Ciba Geigy Ag | Verfahren zur Herstellung von Epothilon A und B und Derivaten |
| DE19636343C1 (de) * | 1996-08-30 | 1997-10-23 | Schering Ag | Zwischenprodukte innerhalb der Totalsynthese von Epothilon A und B |
| DE19645361A1 (de) | 1996-08-30 | 1998-04-30 | Ciba Geigy Ag | Zwischenprodukte innerhalb der Totalsynthese von Epothilon A und B, Teil II |
| DK1367057T3 (da) | 1996-11-18 | 2009-01-19 | Biotechnolog Forschung Gmbh | Epothiloner E og F |
| US6515016B2 (en) | 1996-12-02 | 2003-02-04 | Angiotech Pharmaceuticals, Inc. | Composition and methods of paclitaxel for treating psoriasis |
| US6204388B1 (en) | 1996-12-03 | 2001-03-20 | Sloan-Kettering Institute For Cancer Research | Synthesis of epothilones, intermediates thereto and analogues thereof |
| WO1999001124A1 (en) * | 1996-12-03 | 1999-01-14 | Sloan-Kettering Institute For Cancer Research | Synthesis of epothilones, intermediates thereto, analogues and uses thereof |
| US6380394B1 (en) | 1996-12-13 | 2002-04-30 | The Scripps Research Institute | Epothilone analogs |
| US6441186B1 (en) | 1996-12-13 | 2002-08-27 | The Scripps Research Institute | Epothilone analogs |
| DE19701758A1 (de) | 1997-01-20 | 1998-07-23 | Wessjohann Ludgar A Dr | Epothilone-Synthesebausteine |
| PT975638E (pt) | 1997-02-25 | 2002-12-31 | Biotechnolog Forschung Mbh Gbf | Epothilons modificados nas cadeias laterais |
| DE19713970B4 (de) | 1997-04-04 | 2006-08-31 | R&D-Biopharmaceuticals Gmbh | Epothilone-Synthesebausteine II - Prenylderivate |
| WO1998047891A1 (de) | 1997-04-18 | 1998-10-29 | Studiengesellschaft Kohle Mbh | Selektive olefinmetathese von bi- oder polyfunktionellen substraten in komprimiertem kohlendioxid als reaktionsmedium |
| DE19720312A1 (de) | 1997-05-15 | 1998-11-19 | Hoechst Ag | Zubereitung mit erhöhter in vivo Verträglichkeit |
| DE19821954A1 (de) | 1997-05-15 | 1998-11-19 | Biotechnolog Forschung Gmbh | Verfahren zur Herstellung eines Epothilon-Derivats |
| DE19726627A1 (de) | 1997-06-17 | 1998-12-24 | Schering Ag | Zwischenprodukte, Verfahren zu ihrer Herstellung und ihre Verwendung zur Herstellung von Epothilon |
| US6605599B1 (en) * | 1997-07-08 | 2003-08-12 | Bristol-Myers Squibb Company | Epothilone derivatives |
| US6384230B1 (en) | 1997-07-16 | 2002-05-07 | Schering Aktiengesellschaft | Thiazole derivatives, method for their production and use |
| ES2290993T3 (es) | 1997-08-09 | 2008-02-16 | Bayer Schering Pharma Aktiengesellschaft | Nuevos derivados de epotilona, proceso para su produccion y su utilizacion farmaceutica. |
| US6365749B1 (en) | 1997-12-04 | 2002-04-02 | Bristol-Myers Squibb Company | Process for the preparation of ring-opened epothilone intermediates which are useful for the preparation of epothilone analogs |
| SK287775B6 (sk) | 1998-02-05 | 2011-09-05 | Novartis Ag | Farmaceutická formulácia obsahujúca epothilon, infúzny roztok a použitie farmaceutickej formulácie |
| US6194181B1 (en) | 1998-02-19 | 2001-02-27 | Novartis Ag | Fermentative preparation process for and crystal forms of cytostatics |
| FR2775187B1 (fr) * | 1998-02-25 | 2003-02-21 | Novartis Ag | Utilisation de l'epothilone b pour la fabrication d'une preparation pharmaceutique antiproliferative et d'une composition comprenant l'epothilone b comme agent antiproliferatif in vivo |
| DE69927790T2 (de) | 1998-02-25 | 2006-07-20 | Sloan-Kettering Institute For Cancer Research | Synthese von epothilonen, ihren zwischenprodukten und analogen verbindungen |
| US6399638B1 (en) * | 1998-04-21 | 2002-06-04 | Bristol-Myers Squibb Company | 12,13-modified epothilone derivatives |
| WO2000000485A1 (de) | 1998-06-30 | 2000-01-06 | Schering Aktiengesellschaft | Epothilon-derivate, verfahren zu deren herstellung, zwischenprodukte und ihre pharmazeutische verwendung |
| NZ511722A (en) | 1998-11-20 | 2004-05-28 | Kosan Biosciences Inc | Recombinant methods and materials for producing epothilone and epothilone derivatives |
| CN1122668C (zh) | 1998-12-22 | 2003-10-01 | 诺瓦提斯公司 | 环氧噻酮衍生物，其制备方法及其药物组合物 |
| YU59001A (sh) | 1999-02-18 | 2005-07-19 | Schering Ag. | 16-halogen-epotilon-derivati, postupak za njihovo dobijanje i njihova farmaceutska primena |
| US6211412B1 (en) | 1999-03-29 | 2001-04-03 | The University Of Kansas | Synthesis of epothilones |
| AR023792A1 (es) | 1999-04-30 | 2002-09-04 | Bayer Schering Pharma Ag | Derivados 6-alquenilo- y 6-alquinilo-epotilona, los procedimientos para prepararlos y su empleo en productos farmaceuticos |
| NZ526871A (en) | 2001-01-25 | 2006-01-27 | Bristol Myers Squibb Co | Pharmaceutical dosage forms of epothilones for oral administration |
| AU2002245296B2 (en) | 2001-01-25 | 2006-12-21 | Bristol-Myers Squibb Company | Methods of administering epothilone analogs for the treatment of cancer |
| WO2002072085A1 (en) | 2001-03-14 | 2002-09-19 | Bristol-Myers Squibb Company | Combination of epothilone analogs and chemotherapeutic agents for the treatment of proliferative diseases |
-
2002
- 2002-01-22 NZ NZ526871A patent/NZ526871A/en unknown
- 2002-01-22 WO PCT/US2002/001693 patent/WO2002058699A1/en not_active Ceased
- 2002-01-25 WO PCT/US2002/002518 patent/WO2002058701A1/en not_active Ceased
- 2002-01-25 KR KR10-2003-7009781A patent/KR20040025888A/ko not_active Withdrawn
- 2002-01-25 MX MXPA03006476A patent/MXPA03006476A/es unknown
- 2002-01-25 HR HR20030674A patent/HRP20030674A2/hr not_active Application Discontinuation
- 2002-01-25 CN CNB028069927A patent/CN1268336C/zh not_active Expired - Fee Related
- 2002-01-25 UY UY27138A patent/UY27138A1/es not_active Application Discontinuation
- 2002-01-25 BR BR0206695-5A patent/BR0206695A/pt not_active IP Right Cessation
- 2002-01-25 YU YU58103A patent/YU58103A/sh unknown
- 2002-01-25 PE PE2002000061A patent/PE20020853A1/es not_active Application Discontinuation
- 2002-01-25 PL PL02368636A patent/PL368636A1/xx not_active Application Discontinuation
- 2002-01-25 IL IL15675902A patent/IL156759A0/xx unknown
- 2002-01-25 CA CA002434584A patent/CA2434584A1/en not_active Abandoned
- 2002-01-25 US US10/057,390 patent/US6576651B2/en not_active Ceased
- 2002-01-25 SK SK921-2003A patent/SK9212003A3/sk unknown
- 2002-01-25 CZ CZ20032023A patent/CZ20032023A3/cs unknown
- 2002-01-25 EP EP02723073A patent/EP1361877A1/en not_active Withdrawn
- 2002-01-25 EE EEP200300329A patent/EE200300329A/xx unknown
- 2002-01-25 JP JP2002559035A patent/JP2004528287A/ja not_active Withdrawn
- 2002-01-25 TW TW091101287A patent/TWI250017B/zh not_active IP Right Cessation
- 2002-01-25 RU RU2003126174/15A patent/RU2291695C2/ru not_active IP Right Cessation
- 2002-01-25 HU HU0303800A patent/HUP0303800A3/hu unknown
- 2002-01-25 AR ARP020100288A patent/AR035078A1/es unknown
-
2003
- 2003-07-24 NO NO20033343A patent/NO20033343L/no not_active Application Discontinuation
- 2003-07-24 IS IS6892A patent/IS6892A/is unknown
- 2003-07-24 BG BG108027A patent/BG108027A/bg unknown
-
2005
- 2005-06-09 US US11/149,501 patent/USRE40387E1/en not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| EP1361877A1 (en) | 2003-11-19 |
| YU58103A (sh) | 2006-03-03 |
| CN1498106A (zh) | 2004-05-19 |
| BR0206695A (pt) | 2004-04-20 |
| HUP0303800A3 (en) | 2005-02-28 |
| TWI250017B (en) | 2006-03-01 |
| WO2002058699A1 (en) | 2002-08-01 |
| SK9212003A3 (en) | 2004-11-03 |
| RU2291695C2 (ru) | 2007-01-20 |
| PL368636A1 (en) | 2005-04-04 |
| USRE40387E1 (en) | 2008-06-17 |
| AU2002253880B2 (en) | 2006-11-09 |
| MXPA03006476A (es) | 2003-09-22 |
| PE20020853A1 (es) | 2002-09-27 |
| KR20040025888A (ko) | 2004-03-26 |
| CN1268336C (zh) | 2006-08-09 |
| EE200300329A (et) | 2003-10-15 |
| RU2003126174A (ru) | 2005-02-27 |
| CZ20032023A3 (cs) | 2005-03-16 |
| NO20033343D0 (no) | 2003-07-24 |
| NZ526871A (en) | 2006-01-27 |
| BG108027A (bg) | 2004-12-30 |
| WO2002058701A1 (en) | 2002-08-01 |
| IS6892A (is) | 2003-07-24 |
| HUP0303800A2 (hu) | 2004-03-29 |
| AR035078A1 (es) | 2004-04-14 |
| HRP20030674A2 (en) | 2005-06-30 |
| JP2004528287A (ja) | 2004-09-16 |
| US6576651B2 (en) | 2003-06-10 |
| CA2434584A1 (en) | 2002-08-01 |
| IL156759A0 (en) | 2004-02-08 |
| US20020177615A1 (en) | 2002-11-28 |
| UY27138A1 (es) | 2002-08-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO20033343D0 (no) | Farmasöytiske doseringsformer av epothiloner for oral administrasjon | |
| PL356358A1 (en) | Solid dosage form of someticone for oral administration | |
| NO20034689D0 (no) | Farmasöytiske doseringsformer av amorf nelfinavir mesylat | |
| IL166489A (en) | Oral dosage form in single-dose administration containing at least two layers for the administration and use of flipridone | |
| CY2018005I2 (el) | Απο του στοματος φαρμακοτεχνικες μορφες της κλαντριβινης | |
| HRP20040545A2 (en) | Pharmaceutical compositions of orally active taxane derivatives having enhanced bioavailability | |
| NO20004823D0 (no) | Nye galeniske formuleringer av meloksicam for oral administrering | |
| IL162843A0 (en) | Dosage form for oral administration of a pde4 inhibitor | |
| NO20042842L (no) | Farmasoytiske formuleringer av platina-derivat | |
| EP1383518A4 (en) | ORAL DELIVERY OF MACROMOLECULES | |
| NO20035438L (no) | Farmasoytisk formulering for effektiv administrering av apomorfin, 6aR-(-)-N-propyl-norapomorfin og deres derivater og prodrugs derav | |
| PL372773A1 (en) | Oral administration of epothilones | |
| NO20014738L (no) | Tolperisonholdig farmasöytisk preparat for oral administrering | |
| DE60317803D1 (de) | Pharmazeutische zusammensetzungen enthaltend cyclosporin zur oralen verabreichung | |
| FI20000780L (fi) | Peroraalinen lääkemuoto lääkeaineen hallituksi vapauttamiseksi | |
| NO20040047L (no) | Farmasoytisk formulering for intramuskulaer administrering av fulvestrant | |
| EE200300501A (et) | Ninna manustatavad imidasotriasinooni sisaldavad kompositsioonid | |
| NO20025394D0 (no) | Formuleringer inneholdende et glukokorticoid legemiddel for behandling av bronkopulmonire sykdommer | |
| NO20043007L (no) | Farmasoytisk suspensjon for oral administrering | |
| NO20043633L (no) | Oral doseringsform for kontrollert medikamentfrigivning | |
| NO20032581D0 (no) | Farmasöytisk formulering av gepiron for oral administrering | |
| NO20050183L (no) | Farmasoytiske salter av reboxetin | |
| ITTO20020672A0 (it) | Composizioni farmaceutiche contenenti cheto-acidi per somministrazione endoperitoneale | |
| IL175556A0 (en) | Pharmaceutical composition for oral administration of a pyrazol-3-carboxamide derivative | |
| EP1361866A4 (en) | EMULSIONS AS SOLID DOSAGE FORMS FOR ORAL ADMINISTRATION |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC2A | Withdrawal, rejection or dismissal of laid open patent application |